F‐Box Protein 32 (FBXO32) is markedly overexpressed in hepatocellular carcinoma and facilitates tumor progression by activating the PI3K–AKT signaling pathway via PHLPP2 degradation, underscoring its potential as a promising therapeutic target. Here, PHLPP2 is linked to neoplasm.